M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical Business ReviewThe acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Business Review The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. M&A / DealsRead full story Post navigation Previous: Adcendo secures $75m in Series C funding for ADC developmentNext: Lilly to acquire CrossBridge Bio for up to $300m Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
